|
US5631271A
(en)
|
1986-11-29 |
1997-05-20 |
Serfontein; Willem J. |
Methods and preparations for the treatment and prophylaxis of metabolic disturbances
|
|
US5874285A
(en)
|
1996-09-13 |
1999-02-23 |
Incyte Pharmaceuticals, Inc. |
Polynucleotide encoding a novel human nm23-like protein
|
|
US6818749B1
(en)
|
1998-10-31 |
2004-11-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Variants of humanized anti carcinoma monoclonal antibody cc49
|
|
CA2384713A1
(en)
|
1999-09-29 |
2001-04-05 |
Human Genome Sciences, Inc. |
Colon and colon cancer associated polynucleotides and polypeptides
|
|
CA2491017A1
(en)
|
2002-07-03 |
2004-01-15 |
Immunogen, Inc. |
Antibodies to non-shed muc1 and muc16, and uses thereof
|
|
WO2004050860A2
(en)
|
2002-12-04 |
2004-06-17 |
Diadexus, Inc. |
Compositions, splice variants and methods relating to colon specific genes and proteins
|
|
CA2611728A1
(en)
|
2005-06-08 |
2006-12-14 |
Millennium Pharmaceuticals, Inc. |
Methods for the identification, assessment, and treatment of patients with cancer therapy
|
|
US20100254996A1
(en)
|
2007-06-18 |
2010-10-07 |
Medimmune, Llc |
Synergistic treatment of cells that express epha2 and erbb2
|
|
DK2334703T3
(en)
|
2008-09-17 |
2015-10-05 |
Innate Pharma |
Configurations and methods for detection of tlr3
|
|
US20170204191A1
(en)
|
2008-10-06 |
2017-07-20 |
Cynthia C. Bamdad |
Muc1* antibodies
|
|
US20110195089A1
(en)
|
2008-10-08 |
2011-08-11 |
The Adminstrators Of The Tulane Educational Fund |
Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
|
|
SG176801A1
(en)
|
2009-06-11 |
2012-01-30 |
Minerva Biotechnologies Corp |
Methods for culturing stem and progenitor cells
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP2768945B1
(en)
|
2011-10-17 |
2022-01-05 |
Minerva Biotechnologies Corporation |
Media for stem cell proliferation and induction
|
|
CA2864872C
(en)
|
2012-02-24 |
2022-07-05 |
Alteogen Inc. |
Modified antibody in which motif comprising cysteine residue is bound
|
|
AU2013243948A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins associated with human disease
|
|
CN111849874A
(zh)
|
2012-07-24 |
2020-10-30 |
米纳瓦生物技术公司 |
Nme变体物种表达和抑制
|
|
CN104717980A
(zh)
|
2012-08-14 |
2015-06-17 |
米纳瓦生物技术公司 |
干细胞增强疗法
|
|
CA2886161A1
(en)
|
2012-09-29 |
2014-04-03 |
The Trustees Of The University Of Pennsylvania |
Veterinary composition and methods for non-surgical neutering and castration
|
|
US20160326263A1
(en)
*
|
2013-02-20 |
2016-11-10 |
Minerva Biotechnologies Corporation |
NME Inhibitors and Methods of Using NME Inhibitors
|
|
IL240695B2
(en)
|
2013-02-20 |
2024-03-01 |
Minerva Biotechnologies Corp |
Nme inhibitors and methods of using nme inhibitors
|
|
CN106414726A
(zh)
|
2014-04-07 |
2017-02-15 |
米纳瓦生物技术公司 |
抗nme抗体
|
|
CA2976089C
(en)
*
|
2015-02-10 |
2026-01-13 |
Minerva Biotechnologies Corporation |
Humanized anti-muc1* antibodies
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
WO2018010140A1
(zh)
*
|
2016-07-14 |
2018-01-18 |
中国科学院生物物理研究所 |
I型干扰素受体抗体及其用途
|
|
WO2018054240A1
(en)
|
2016-09-20 |
2018-03-29 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pcsk9 antibodies
|
|
JP2020500031A
(ja)
|
2016-10-11 |
2020-01-09 |
ミネルバ バイオテクノロジーズ コーポレーション |
ヒト化抗ｍｕｃ１＊抗体及び開裂酵素の使用
|
|
WO2019104306A1
(en)
|
2017-11-27 |
2019-05-31 |
Minerva Biotechnologies Corporation |
Humanized anti-muc1* antibodies and direct use of cleavage enzyme
|
|
EP3920693A4
(en)
|
2019-02-04 |
2022-10-05 |
Minerva Biotechnologies Corporation |
ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
|
|
CN116367857A
(zh)
|
2020-06-08 |
2023-06-30 |
米纳瓦生物技术公司 |
抗nme抗体及治疗癌症或癌症转移的方法
|
|
KR20230028796A
(ko)
|
2020-06-26 |
2023-03-02 |
미네르바 바이오테크놀로지 코포레이션 |
항-nme 항체 및 암 또는 암 전이의 치료 방법
|